Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines.
OBJECTIVE
To produce up-to-date clinical practice guidelines on the prevention of venous thromboembolism in surgery and obstetrics.


METHODS
A Steering Committee defined the scope of the topic, the questions to be answered, and the assessment criteria. Eight multidisciplinary working groups (total of 70 experts) performed a critical appraisal of the literature in the following disciplines: pharmacology of antithrombotic agents, orthopaedics; general surgery (gastrointestinal (GI) and varicose vein surgery); urology; gynaecology and obstetrics; thoracic, cardiac and vascular surgery; surgery of the head, neck and spine; and surgery of burns patients. The resultant reports and guidelines were submitted for comment and completion of the Appraisal of Guidelines Research & Evaluation questionnaire to a total of 150 peer reviewers, before producing definite guidelines.


RESULTS
The report answers the following questions for each type of surgery: (i) What is the venous thromboembolism incidence according to clinical and/or paraclinical criteria in the absence of prophylaxis? (with stratification of venous thromboembolism risk into low, moderate and high categories); (ii) What is the efficacy and safety of the prophylactic measures used? (iii) When should prophylaxis be introduced and how long should it last? (iv) Does ambulatory surgery affect efficacy and safety of prophylaxis?


CONCLUSIONS
Apart from answering the above questions, the guidelines provide a summary table for each discipline. This table stratifies types of surgery into the three risk categories, specifies the recommended prophylaxis for venous thromboembolism (pharmacological and/or mechanical) and grades each recommendation. In addition, whenever appropriate, the recommended prophylaxis is adjusted to low- and high-risk patients.
Samama
C M
CM
Avicenne University Hospital, Department of Anaesthesiology and Intensive Care, Bobigny, France. casamama@invivo.edu
Albaladejo
P
P
Benhamou
D
D
Bertin-Maghit
M
M
Bruder
N
N
Doublet
J D
JD
Laversin
S
S
Leclerc
S
S
Marret
E
E
Mismetti
P
P
Samain
E
E
Steib
A
A
D000925:Anticoagulants / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control*; D011644:Puerperal Disorders / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000517:prevention & control*; D012307:Risk Factors; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight